KUALA LUMPUR, May 23 (Bernama) -- Invivoscribe Inc, a privately held biotechnology company, has expanded space and testing capabilities in its international network of accredited LabPMM® clinical laboratories.
Additions to the test menu will include morphology, IHC, flow cytometry, as well as the latest multiparameter flow- (MPF) and NGS-based minimal residual disease (MRD) testing of primary specimens.
The newly-added services will further support rapid patient diagnosis, study subject enrolment and stratifications.
They will be available by year-end in San Diego, followed by the clinical laboratories in Japan, Germany and China.
Invivoscribe chief scientific officer and chief executive officer, Dr Jeffrey Miller said the comprehensive test menu would eliminate the need for partners to split primary specimens, dramatically decreasing turnaround times and accelerating receipt of comprehensive test reports.
“This is especially, important for partners performing international clinical trials, as enrolment in frontline therapies often requires timely testing and reporting, which can be delayed when using multiple vendors.”
Invivoscribe’s wholly-owned LabPMM laboratories are accredited per regional requirement and the only clinical reference laboratories offering tests with bioinformatics software developed and manufactured by Invivoscribe in its FDA-registered cGMP facility.
-- BERNAMA
No comments:
Post a Comment